Neurocrine Biosciences, Inc. (NBIX): Price and Financial Metrics
NBIX Price/Volume Stats
| Current price | $132.00 | 52-week high | $148.37 |
| Prev. close | $132.54 | 52-week low | $89.04 |
| Day low | $131.54 | Volume | 140,790 |
| Day high | $133.65 | Avg. volume | 838,056 |
| 50-day MA | $136.08 | Dividend yield | N/A |
| 200-day MA | $120.35 | Market Cap | 13.13B |
NBIX Stock Price Chart Interactive Chart >
Neurocrine Biosciences, Inc. (NBIX) Company Bio
Neurocrine Biosciences discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company was founded in 1992 and is based in San Diego, California.
Latest NBIX News From Around the Web
Below are the latest news stories about NEUROCRINE BIOSCIENCES INC that investors may wish to consider to help them evaluate NBIX as an investment opportunity.
3 Stocks at the Forefront of Medical InnovationBoring businesses and industries typically show new faces when technology comes around; today, these biotech stocks are leading the way. |
13 High Growth Healthcare Stocks to BuyIn this article, we will take a look at 13 high growth healthcare stocks to buy. To skip our analysis of the recent market activity, you can go directly to see the 5 Best High Growth Healthcare Stocks to Buy. For the purpose of this article, we have defined high growth stocks as stocks that […] |
Neurocrine (NBIX) Soars 6.0%: Is Further Upside Left in the Stock?Neurocrine (NBIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term. |
Neurocrine Biosciences' (NASDAQ:NBIX) five-year earnings growth trails the 12% YoY shareholder returnsWhen you buy and hold a stock for the long term, you definitely want it to provide a positive return. Better yet, you'd... |
Here’s Why Neurocrine Biosciences (NBIX) Rose in Q3Harding Loevner, an asset management company, released its “Global Small Companies Equity Strategy” third-quarter 2023 investor letter. A copy of the same can be downloaded here. Global small caps fell sharply in the third quarter. Japan was the weakest region, although returns in healthcare were good and industrials detracted. The strategy returned -5.36% (net) compared to […] |
NBIX Price Returns
| 1-mo | -6.15% |
| 3-mo | -3.91% |
| 6-mo | 19.52% |
| 1-year | 26.24% |
| 3-year | 37.27% |
| 5-year | 68.30% |
| YTD | 0.18% |
| 2023 | 10.31% |
| 2022 | 40.24% |
| 2021 | -11.14% |
| 2020 | -10.83% |
| 2019 | 50.53% |
Continue Researching NBIX
Want to do more research on Neurocrine Biosciences Inc's stock and its price? Try the links below:Neurocrine Biosciences Inc (NBIX) Stock Price | Nasdaq
Neurocrine Biosciences Inc (NBIX) Stock Quote, History and News - Yahoo Finance
Neurocrine Biosciences Inc (NBIX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...